Steroid-containing ophthalmic solutions more likely to be contaminated

Article

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free.

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free, according to a report published in the October issue of the British Journal of Ophthalmology.

Danny H-Kauffmann Jokl and colleagues from the New York Medical College, New York, USA conducted a study to assess the frequency of ophthalmic solution contamination in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria and the results were analysed according to the therapeutic class of the solution, how long the bottle was in use for and the appearance of the bottle upon visual inspection.

Ten (8%) of the solutions were contaminated with bacteria: four of eight steroid-containing anti-inflammatory solutions, two of six combination antimicrobial and steroid-containing anti-inflammatory solutions, two of 34 solutions for the treatment of glaucoma and two of 57 medications for dry eye. None of the mydriatic, miotic or non-combination antimicrobial solutions were found to be contaminated.

Just 30% of the contaminated bottles were considered "dirty" under visual inspection. Neither length of time that bottles had been in use or appearance of the bottles were found to be predictors of contamination.

The frequent contamination during reuse of certain steroid-containing ophthalmic solutions has led the research team to suggest that single-use solutions may be preferable.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.